Cancer Biology and Molecular Therapeutics
癌症生物学和分子治疗
基本信息
- 批准号:7921845
- 负责人:
- 金额:$ 10.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This application requests continued support for a training program in Cancer Biology and Molecular Therapeutics that was begun in 1990. The program trains predoctoral and postdoctoral fellows in the fundamentals of cancer research by participation in didactic courses, seminars, discussion groups and performance of laboratory-based research. The training program is integrated into the research programs of the Morris Cotton Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, thereby enhancing exposure to many facets of the disease. This is a multidisciplinary program drawing together 20 faculty with appointments in 7 different academic programs. The faculty have recently been brought together in a new Cancer Biology graduate program under an umbrella Program in Experimental and Molecular Medicine (PEMM). Predoctoral students are enrolled in the PEMM program in year 1 and then select one of five themes in which they undertake their thesis research, journal clubs and seminars. Students who select Cancer Biology then become the responsibility of the Cancer Biology Graduate Program for the remainder of their training. Required didactic work includes courses in Cancer Biology, Oncogenomics, and the Ethical Conduct of Research. Currently there are 43 PhD or MD/PhD students in the laboratories of the training faculty. Students are recruited to the Training Grant after they have completed one or more years in the graduate program, and have selected a faculty mentor. This allows their performance in first year classes and research rotations to be used as evidence of their potential to succeed in the PhD program. Postdoctoral trainees are engaged in fulltime research under the mentorship of a faculty adviser, but have their research experience broadened by regular interactions with other faculty and fellows through conferences, seminars and programmatic activities. There are currently 30 postdoctoral trainees in the laboratories of the faculty. Training grant funds are used to facilitate recruitment of postdoctoral trainees, who then are encouraged to obtain alternate extramural funding, thereby enhancing the ability of the program to recruit additional trainees. This mechanism also facilitates the recruitment of minority applicants as there is a more frequent turnover of positions, and hence funds can be assigned to any qualified minority as soon as identified. This training program has had an outstanding record of achievement since its inception, and this will be further strengthened by the focused training under the new Cancer Biology Graduate Program. This new direction for the program was achieved in major part by the established track record of this training program, and as a consequence we are requesting continued support at the current level of training positions.
描述(由申请人提供):本申请要求继续支持1990年开始的癌症生物学和分子治疗学培训计划。该计划通过参与教学课程,研讨会,讨论小组和实验室研究的表现,培养癌症研究基础的博士前和博士后研究员。培训计划被纳入莫里斯棉花癌症中心的研究计划,国家癌症研究所指定的综合癌症中心,从而提高了对疾病的许多方面的接触。这是一个多学科课程,吸引了20名教师,他们在7个不同的学术课程中任职。该学院最近在实验和分子医学(PEMM)伞计划下的新癌症生物学研究生课程中聚集在一起。博士前学生在第1年参加PEMM课程,然后选择五个主题之一,他们进行论文研究,期刊俱乐部和研讨会。谁选择癌症生物学的学生,然后成为癌症生物学研究生课程的责任,为他们的培训的其余部分。所需的教学工作包括癌症生物学,癌基因组学和研究的道德行为课程。目前有43名博士或MD/博士生在培训学院的实验室。学生被招募到培训补助金后,他们已经完成了一年或多年的研究生课程,并选择了教师导师。这使得他们在第一年的课程和研究轮换中的表现可以作为他们在博士课程中取得成功的潜力的证据。博士后学员在教师顾问的指导下从事全职研究,但通过会议,研讨会和方案活动与其他教师和研究员的定期互动扩大了他们的研究经验。目前有30名博士后在学院的实验室实习。培训补助金资金用于促进博士后学员的招聘,然后鼓励他们获得替代的校外资金,从而提高该计划招聘更多学员的能力。这一机制还有助于招聘少数群体申请人,因为职位的更替更加频繁,因此,一旦确定符合条件的少数群体,就可以向其分配资金。该培训计划自成立以来取得了杰出的成就,这将通过新的癌症生物学研究生课程的重点培训得到进一步加强。该计划的这一新方向在很大程度上是通过该培训计划的既定记录实现的,因此,我们要求在目前的培训职位水平上继续提供支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN R EASTMAN其他文献
ALAN R EASTMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN R EASTMAN', 18)}}的其他基金
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7483072 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
8633002 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7629019 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
9036264 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7257577 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7864084 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
8499599 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
9243917 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
8074512 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
相似国自然基金
Kidney injury molecular(KIM-1)介导肾小管上皮细胞自噬在糖尿病肾病肾间质纤维化中的作用
- 批准号:81300605
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
Molecular Plant
- 批准号:31224801
- 批准年份:2012
- 资助金额:20.0 万元
- 项目类别:专项基金项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
Molecular Plant
- 批准号:31024802
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:专项基金项目
Cellular & Molecular Immunology
- 批准号:30824806
- 批准年份:2008
- 资助金额:20.0 万元
- 项目类别:专项基金项目
相似海外基金
Exploration of immunogenetic and molecular basis of hypertensive disease aiming at establishment of novel preventive and therapeutic strategies
探索高血压疾病的免疫遗传学和分子基础,旨在建立新的预防和治疗策略
- 批准号:
23K05615 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
晚期前列腺癌中 Trop-2 的分子调控和表达:确定最佳治疗领域
- 批准号:
10735996 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Unveiling the molecular basis of chromatinopathies to delineate innovative therapeutic solutions
揭示染色质病变的分子基础,描绘创新的治疗解决方案
- 批准号:
EP/X027007/1 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Research Grant
Elucidation of molecular mechanisms related to smoking and inflammatory factors and establishment of novel therapeutic strategies for ARDS
阐明吸烟和炎症因子相关的分子机制并建立ARDS新的治疗策略
- 批准号:
23K08445 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of molecular targeted therapeutic measures against canine babesiosis
犬巴贝斯虫病分子靶向治疗措施的开发
- 批准号:
22KF0016 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Molecular MR-PET to characterize malignant transformation and identify therapeutic vulnerabilities in human IDH-mutant gliomas
分子 MR-PET 表征人类 IDH 突变神经胶质瘤的恶性转化并确定治疗脆弱性
- 批准号:
10750893 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Molecular Characteristics and Therapeutic Efficacy of PD-1 Inhibitors in MSI-H/dMMR Colorectal Cancer
PD-1抑制剂在MSI-H/dMMR结直肠癌中的分子特征和治疗效果
- 批准号:
23K15479 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms and structural determinants of pharmacological chaperone action; therapeutic potential for the treatment of early onset severe obesity
药理学伴侣作用的分子机制和结构决定因素;
- 批准号:
478493 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Operating Grants
Elucidation of the molecular mechanism of p53 stabilization of USP10 in hepatocellular carcinoma and development of novel therapeutic strategy
阐明p53稳定USP10在肝细胞癌中的分子机制并开发新的治疗策略
- 批准号:
23K15483 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
MiT/TFE 易位肾细胞癌中激活的 NRF2 信号传导的分子机制和治疗靶向
- 批准号:
10633699 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别: